Comment on

• Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.

  Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Léonard P, Moreels A, Haumont M, Bollen A, Smets F, Denis M. Sokal EM, et al. J Infect Dis. 2007 Dec 15;196(12):1749-53. doi: 10.1086/523813. J Infect Dis. 2007. PMID: 18190254 Clinical Trial.